ABCG2 aptamer selectively delivers doxorubicin to drug-resistant breast cancer cells View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-04-09

AUTHORS

Shirin Hashemitabar, Rezvan Yazdian-Robati, Maryam Hashemi, Mohammad Ramezani, Khalil Abnous, Fatemeh Kalalinia

ABSTRACT

Chemotherapy is the most widely used treatment for cancer therapy, but its efficacy is limited by the side effects of non-specific cytotoxic drugs. Ligand-based targeting drug-delivery system is a solution to circumvent this issue. In this study, an ABCG2 aptamer–doxorubicin complex was prepared, and its efficacy in targeted drug delivery to mitoxantrone-resistance breast cancer cell line (MCF7/MX) was evaluated. The formation of aptamer–doxorubicin physical complex was analyzed by fluorometric analysis. The cytotoxicities of doxorubicin and aptamer–doxorubicin complex on MCF7 and MCF7/MX cell lines were evaluated by the MTT assay, and IC50 values were obtained. Cellular uptake of aptamer–doxorubicin complex was assessed by flow cytometry cellular uptake assay. Results: Fluorometric analysis of aptamer–doxorubicin showed 1–1.5 molar ratio of the drug to the aptamer could efficiently quench Dox fluorescence. MTT assay results showed that MCF7/MX cells were more resistant to doxorubicin than MCF7 cells (IC50 : 3.172 ± 0.536 and 1.456 ± 0.154 μM, respectively). Flow cytometry and MTT assay results showed that the aptamer–doxorubicin complex could increase the uptake and cytotoxicity of doxorubicin in MCF7/MX cell line in comparison with free doxorubicin, while the same treatments had no effect on IC50 of Dox on MCF7 cells. The results proposed that the ABCG2 aptamer–drug complex can be effectively used for specific drug delivery to ABCG2-overexpressing cells. More... »

PAGES

39

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12038-019-9854-x

DOI

http://dx.doi.org/10.1007/s12038-019-9854-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113330484

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/31180052


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biological Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "ATP Binding Cassette Transporter, Subfamily G, Member 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibiotics, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aptamers, Nucleotide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biological Transport", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Doxorubicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Carriers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gene Expression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glycoconjugates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "MCF-7 Cells", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Molecular Targeted Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Binding", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Biotechnology Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran", 
          "id": "http://www.grid.ac/institutes/grid.411583.a", 
          "name": [
            "Biotechnology Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hashemitabar", 
        "givenName": "Shirin", 
        "id": "sg:person.012301325267.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012301325267.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Molecular and Cell biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran", 
          "id": "http://www.grid.ac/institutes/grid.411623.3", 
          "name": [
            "Molecular and Cell biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yazdian-Robati", 
        "givenName": "Rezvan", 
        "id": "sg:person.0647016307.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647016307.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nanotechnology Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran", 
          "id": "http://www.grid.ac/institutes/grid.411583.a", 
          "name": [
            "Nanotechnology Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hashemi", 
        "givenName": "Maryam", 
        "id": "sg:person.01344241006.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344241006.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pharmaceutical Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran", 
          "id": "http://www.grid.ac/institutes/grid.411583.a", 
          "name": [
            "Nanotechnology Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran", 
            "Pharmaceutical Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ramezani", 
        "givenName": "Mohammad", 
        "id": "sg:person.0633411431.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633411431.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medicinal Chemistry Department, Academy of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran", 
          "id": "http://www.grid.ac/institutes/grid.411583.a", 
          "name": [
            "Pharmaceutical Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran", 
            "Medicinal Chemistry Department, Academy of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Abnous", 
        "givenName": "Khalil", 
        "id": "sg:person.01106117210.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106117210.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Genetic Research Center, Mashhad University of Medical Sciences, Mashhad, Iran", 
          "id": "http://www.grid.ac/institutes/grid.411583.a", 
          "name": [
            "Biotechnology Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran", 
            "Genetic Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kalalinia", 
        "givenName": "Fatemeh", 
        "id": "sg:person.01354672317.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354672317.51"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nm1186", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013405508", 
          "https://doi.org/10.1038/nm1186"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1208/s12248-014-9668-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032407622", 
          "https://doi.org/10.1208/s12248-014-9668-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00432-010-0893-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015219571", 
          "https://doi.org/10.1007/s00432-010-0893-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11095-016-1967-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025727940", 
          "https://doi.org/10.1007/s11095-016-1967-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11010-011-1191-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015241139", 
          "https://doi.org/10.1007/s11010-011-1191-9"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-04-09", 
    "datePublishedReg": "2019-04-09", 
    "description": "Chemotherapy is the most widely used treatment for cancer therapy, but its efficacy is limited by the side effects of non-specific cytotoxic drugs. Ligand-based targeting drug-delivery system is a solution to circumvent this issue. In this study, an ABCG2 aptamer\u2013doxorubicin complex was prepared, and its efficacy in targeted drug delivery to mitoxantrone-resistance breast cancer cell line (MCF7/MX) was evaluated. The formation of aptamer\u2013doxorubicin physical complex was analyzed by fluorometric analysis. The cytotoxicities of doxorubicin and aptamer\u2013doxorubicin complex on MCF7 and MCF7/MX cell lines were evaluated by the MTT assay, and IC50 values were obtained. Cellular uptake of aptamer\u2013doxorubicin complex was assessed by flow cytometry cellular uptake assay. Results: Fluorometric analysis of aptamer\u2013doxorubicin showed 1\u20131.5 molar ratio of the drug to the aptamer could efficiently quench Dox fluorescence. MTT assay results showed that MCF7/MX cells were more resistant to doxorubicin than MCF7 cells (IC50 : 3.172\u2009\u00b1\u20090.536 and 1.456\u2009\u00b1\u20090.154\u00a0\u03bcM, respectively). Flow cytometry and MTT assay results showed that the aptamer\u2013doxorubicin complex could increase the uptake and cytotoxicity of doxorubicin in MCF7/MX cell line in comparison with free doxorubicin, while the same treatments had no effect on IC50 of Dox on MCF7 cells. The results proposed that the ABCG2 aptamer\u2013drug complex can be effectively used for specific drug delivery to ABCG2-overexpressing cells.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12038-019-9854-x", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1092026", 
        "issn": [
          "0250-5991", 
          "0973-7138"
        ], 
        "name": "Journal of Biosciences", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "44"
      }
    ], 
    "keywords": [
      "aptamer\u2013doxorubicin complex", 
      "drug delivery", 
      "cytotoxicity of doxorubicin", 
      "drug delivery systems", 
      "specific drug delivery", 
      "drug-resistant breast cancer cells", 
      "cellular uptake assays", 
      "cell lines", 
      "MCF7/MX cells", 
      "non-specific cytotoxic drugs", 
      "MCF7 cells", 
      "breast cancer cell lines", 
      "breast cancer cells", 
      "DOX fluorescence", 
      "molar ratio", 
      "free doxorubicin", 
      "IC50 of DOX", 
      "cancer cell lines", 
      "cellular uptake", 
      "side effects", 
      "complexes", 
      "MX cells", 
      "cytotoxic drugs", 
      "aptamer", 
      "MTT assay results", 
      "fluorometric analysis", 
      "cancer cells", 
      "MTT assay", 
      "cancer therapy", 
      "IC50 values", 
      "doxorubicin", 
      "uptake assays", 
      "same treatment", 
      "drugs", 
      "assay results", 
      "efficacy", 
      "cells", 
      "treatment", 
      "cytotoxicity", 
      "delivery", 
      "assays", 
      "chemotherapy", 
      "therapy", 
      "DOX", 
      "uptake", 
      "cytometry", 
      "ABCG2", 
      "fluorescence", 
      "IC50", 
      "MTT", 
      "MCF7", 
      "physical complex", 
      "formation", 
      "solution", 
      "effect", 
      "lines", 
      "study", 
      "results", 
      "analysis", 
      "ratio", 
      "comparison", 
      "values", 
      "system", 
      "issues"
    ], 
    "name": "ABCG2 aptamer selectively delivers doxorubicin to drug-resistant breast cancer cells", 
    "pagination": "39", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113330484"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12038-019-9854-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "31180052"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12038-019-9854-x", 
      "https://app.dimensions.ai/details/publication/pub.1113330484"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-10T10:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220509/entities/gbq_results/article/article_797.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12038-019-9854-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12038-019-9854-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12038-019-9854-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12038-019-9854-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12038-019-9854-x'


 

This table displays all metadata directly associated to this object as RDF triples.

252 TRIPLES      22 PREDICATES      110 URIs      98 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12038-019-9854-x schema:about N005adb5b000844fd90d1ffc29ac876df
2 N0081031e5f5b4039a693f6360c78389a
3 N0dccfdfb9c2e49dbb44fb65fd4791fd0
4 N395483464a02436aaa4772c38b5086d4
5 N44d9c7977fdd424da76c7fbc37afcf41
6 N4c0811c17a214de78fc6bcf1a75f35ab
7 N53772dda41b941fb9a924927e5581636
8 N6876757f3e2845a8a2ed692d58eb979a
9 N88ac6b437fc14bba9c7f0fc0d375c468
10 N88eabf5a8b494c99b6c03b35d4b4be48
11 Nac61c97965154986b1721572de2c6a9d
12 Nce3822343ee841faadf08288ed2c5771
13 Nd37c47114d8242f9bddaad769078c182
14 Ndbee54fb87e34058a4e8b2b58fb252f9
15 Ne97a94a84a8c4dae8e88abccde2a74fd
16 Nfd0e221e6a054bf588947d3bb73dfba0
17 anzsrc-for:06
18 schema:author Na8d903c8d5af48868320e7b45804cf95
19 schema:citation sg:pub.10.1007/s00432-010-0893-9
20 sg:pub.10.1007/s11010-011-1191-9
21 sg:pub.10.1007/s11095-016-1967-4
22 sg:pub.10.1038/nm1186
23 sg:pub.10.1208/s12248-014-9668-6
24 schema:datePublished 2019-04-09
25 schema:datePublishedReg 2019-04-09
26 schema:description Chemotherapy is the most widely used treatment for cancer therapy, but its efficacy is limited by the side effects of non-specific cytotoxic drugs. Ligand-based targeting drug-delivery system is a solution to circumvent this issue. In this study, an ABCG2 aptamer–doxorubicin complex was prepared, and its efficacy in targeted drug delivery to mitoxantrone-resistance breast cancer cell line (MCF7/MX) was evaluated. The formation of aptamer–doxorubicin physical complex was analyzed by fluorometric analysis. The cytotoxicities of doxorubicin and aptamer–doxorubicin complex on MCF7 and MCF7/MX cell lines were evaluated by the MTT assay, and IC50 values were obtained. Cellular uptake of aptamer–doxorubicin complex was assessed by flow cytometry cellular uptake assay. Results: Fluorometric analysis of aptamer–doxorubicin showed 1–1.5 molar ratio of the drug to the aptamer could efficiently quench Dox fluorescence. MTT assay results showed that MCF7/MX cells were more resistant to doxorubicin than MCF7 cells (IC50 : 3.172 ± 0.536 and 1.456 ± 0.154 μM, respectively). Flow cytometry and MTT assay results showed that the aptamer–doxorubicin complex could increase the uptake and cytotoxicity of doxorubicin in MCF7/MX cell line in comparison with free doxorubicin, while the same treatments had no effect on IC50 of Dox on MCF7 cells. The results proposed that the ABCG2 aptamer–drug complex can be effectively used for specific drug delivery to ABCG2-overexpressing cells.
27 schema:genre article
28 schema:inLanguage en
29 schema:isAccessibleForFree false
30 schema:isPartOf N74377fae10db43c7acdd84e405149cc0
31 N8b679f26290d47d3bf6d4eaa0f00d5ab
32 sg:journal.1092026
33 schema:keywords ABCG2
34 DOX
35 DOX fluorescence
36 IC50
37 IC50 of DOX
38 IC50 values
39 MCF7
40 MCF7 cells
41 MCF7/MX cells
42 MTT
43 MTT assay
44 MTT assay results
45 MX cells
46 analysis
47 aptamer
48 aptamer–doxorubicin complex
49 assay results
50 assays
51 breast cancer cell lines
52 breast cancer cells
53 cancer cell lines
54 cancer cells
55 cancer therapy
56 cell lines
57 cells
58 cellular uptake
59 cellular uptake assays
60 chemotherapy
61 comparison
62 complexes
63 cytometry
64 cytotoxic drugs
65 cytotoxicity
66 cytotoxicity of doxorubicin
67 delivery
68 doxorubicin
69 drug delivery
70 drug delivery systems
71 drug-resistant breast cancer cells
72 drugs
73 effect
74 efficacy
75 fluorescence
76 fluorometric analysis
77 formation
78 free doxorubicin
79 issues
80 lines
81 molar ratio
82 non-specific cytotoxic drugs
83 physical complex
84 ratio
85 results
86 same treatment
87 side effects
88 solution
89 specific drug delivery
90 study
91 system
92 therapy
93 treatment
94 uptake
95 uptake assays
96 values
97 schema:name ABCG2 aptamer selectively delivers doxorubicin to drug-resistant breast cancer cells
98 schema:pagination 39
99 schema:productId N5ed91c7476d94c3a827d171d0ffb0921
100 N637c1e8215934b28af31498c5a7cf613
101 N63fdc436a41e42e2b80b5cd8f486080b
102 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113330484
103 https://doi.org/10.1007/s12038-019-9854-x
104 schema:sdDatePublished 2022-05-10T10:22
105 schema:sdLicense https://scigraph.springernature.com/explorer/license/
106 schema:sdPublisher Ne6bf4cbaf6c24a2bbb9af22d51322973
107 schema:url https://doi.org/10.1007/s12038-019-9854-x
108 sgo:license sg:explorer/license/
109 sgo:sdDataset articles
110 rdf:type schema:ScholarlyArticle
111 N005adb5b000844fd90d1ffc29ac876df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Antibiotics, Antineoplastic
113 rdf:type schema:DefinedTerm
114 N0081031e5f5b4039a693f6360c78389a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Biological Transport
116 rdf:type schema:DefinedTerm
117 N0dccfdfb9c2e49dbb44fb65fd4791fd0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name MCF-7 Cells
119 rdf:type schema:DefinedTerm
120 N2611c8c982f24d9f8f15a3f9023214a3 rdf:first sg:person.01344241006.86
121 rdf:rest Na735fe95961347e2b0adc56ce5e747bd
122 N395483464a02436aaa4772c38b5086d4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Aptamers, Nucleotide
124 rdf:type schema:DefinedTerm
125 N3e81fa82be67422db6b17ec9fee9ee2e rdf:first sg:person.01106117210.43
126 rdf:rest Nd7105267da4d4ae7a80d9fa5293e688c
127 N44d9c7977fdd424da76c7fbc37afcf41 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Protein Binding
129 rdf:type schema:DefinedTerm
130 N4c0811c17a214de78fc6bcf1a75f35ab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Glycoconjugates
132 rdf:type schema:DefinedTerm
133 N53772dda41b941fb9a924927e5581636 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Gene Expression
135 rdf:type schema:DefinedTerm
136 N5ed91c7476d94c3a827d171d0ffb0921 schema:name dimensions_id
137 schema:value pub.1113330484
138 rdf:type schema:PropertyValue
139 N637c1e8215934b28af31498c5a7cf613 schema:name doi
140 schema:value 10.1007/s12038-019-9854-x
141 rdf:type schema:PropertyValue
142 N63fdc436a41e42e2b80b5cd8f486080b schema:name pubmed_id
143 schema:value 31180052
144 rdf:type schema:PropertyValue
145 N6876757f3e2845a8a2ed692d58eb979a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Doxorubicin
147 rdf:type schema:DefinedTerm
148 N74377fae10db43c7acdd84e405149cc0 schema:volumeNumber 44
149 rdf:type schema:PublicationVolume
150 N88ac6b437fc14bba9c7f0fc0d375c468 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Female
152 rdf:type schema:DefinedTerm
153 N88eabf5a8b494c99b6c03b35d4b4be48 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Neoplasm Proteins
155 rdf:type schema:DefinedTerm
156 N8b679f26290d47d3bf6d4eaa0f00d5ab schema:issueNumber 2
157 rdf:type schema:PublicationIssue
158 Na735fe95961347e2b0adc56ce5e747bd rdf:first sg:person.0633411431.06
159 rdf:rest N3e81fa82be67422db6b17ec9fee9ee2e
160 Na8d903c8d5af48868320e7b45804cf95 rdf:first sg:person.012301325267.68
161 rdf:rest Na97f22eef2bd4eb89ad746a72572ae70
162 Na97f22eef2bd4eb89ad746a72572ae70 rdf:first sg:person.0647016307.65
163 rdf:rest N2611c8c982f24d9f8f15a3f9023214a3
164 Nac61c97965154986b1721572de2c6a9d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Cell Survival
166 rdf:type schema:DefinedTerm
167 Nce3822343ee841faadf08288ed2c5771 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Humans
169 rdf:type schema:DefinedTerm
170 Nd37c47114d8242f9bddaad769078c182 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Cell Line, Tumor
172 rdf:type schema:DefinedTerm
173 Nd7105267da4d4ae7a80d9fa5293e688c rdf:first sg:person.01354672317.51
174 rdf:rest rdf:nil
175 Ndbee54fb87e34058a4e8b2b58fb252f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Molecular Targeted Therapy
177 rdf:type schema:DefinedTerm
178 Ne6bf4cbaf6c24a2bbb9af22d51322973 schema:name Springer Nature - SN SciGraph project
179 rdf:type schema:Organization
180 Ne97a94a84a8c4dae8e88abccde2a74fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name ATP Binding Cassette Transporter, Subfamily G, Member 2
182 rdf:type schema:DefinedTerm
183 Nfd0e221e6a054bf588947d3bb73dfba0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Drug Carriers
185 rdf:type schema:DefinedTerm
186 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
187 schema:name Biological Sciences
188 rdf:type schema:DefinedTerm
189 sg:journal.1092026 schema:issn 0250-5991
190 0973-7138
191 schema:name Journal of Biosciences
192 schema:publisher Springer Nature
193 rdf:type schema:Periodical
194 sg:person.01106117210.43 schema:affiliation grid-institutes:grid.411583.a
195 schema:familyName Abnous
196 schema:givenName Khalil
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106117210.43
198 rdf:type schema:Person
199 sg:person.012301325267.68 schema:affiliation grid-institutes:grid.411583.a
200 schema:familyName Hashemitabar
201 schema:givenName Shirin
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012301325267.68
203 rdf:type schema:Person
204 sg:person.01344241006.86 schema:affiliation grid-institutes:grid.411583.a
205 schema:familyName Hashemi
206 schema:givenName Maryam
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344241006.86
208 rdf:type schema:Person
209 sg:person.01354672317.51 schema:affiliation grid-institutes:grid.411583.a
210 schema:familyName Kalalinia
211 schema:givenName Fatemeh
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354672317.51
213 rdf:type schema:Person
214 sg:person.0633411431.06 schema:affiliation grid-institutes:grid.411583.a
215 schema:familyName Ramezani
216 schema:givenName Mohammad
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633411431.06
218 rdf:type schema:Person
219 sg:person.0647016307.65 schema:affiliation grid-institutes:grid.411623.3
220 schema:familyName Yazdian-Robati
221 schema:givenName Rezvan
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647016307.65
223 rdf:type schema:Person
224 sg:pub.10.1007/s00432-010-0893-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015219571
225 https://doi.org/10.1007/s00432-010-0893-9
226 rdf:type schema:CreativeWork
227 sg:pub.10.1007/s11010-011-1191-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015241139
228 https://doi.org/10.1007/s11010-011-1191-9
229 rdf:type schema:CreativeWork
230 sg:pub.10.1007/s11095-016-1967-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025727940
231 https://doi.org/10.1007/s11095-016-1967-4
232 rdf:type schema:CreativeWork
233 sg:pub.10.1038/nm1186 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013405508
234 https://doi.org/10.1038/nm1186
235 rdf:type schema:CreativeWork
236 sg:pub.10.1208/s12248-014-9668-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032407622
237 https://doi.org/10.1208/s12248-014-9668-6
238 rdf:type schema:CreativeWork
239 grid-institutes:grid.411583.a schema:alternateName Biotechnology Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran
240 Genetic Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
241 Medicinal Chemistry Department, Academy of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
242 Nanotechnology Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran
243 Pharmaceutical Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran
244 schema:name Biotechnology Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran
245 Genetic Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
246 Medicinal Chemistry Department, Academy of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
247 Nanotechnology Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran
248 Pharmaceutical Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran
249 rdf:type schema:Organization
250 grid-institutes:grid.411623.3 schema:alternateName Molecular and Cell biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
251 schema:name Molecular and Cell biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
252 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...